Great Lakes Advisors LLC bought a new stake in TG Therapeutics, Inc. (NASDAQ:TGTX - Free Report) in the second quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm bought 20,124 shares of the biopharmaceutical company's stock, valued at approximately $1,106,000.
Other institutional investors have also made changes to their positions in the company. Danske Bank A S bought a new stake in TG Therapeutics during the 3rd quarter worth about $25,000. EverSource Wealth Advisors LLC increased its position in TG Therapeutics by 51.9% in the 1st quarter. EverSource Wealth Advisors LLC now owns 1,068 shares of the biopharmaceutical company's stock valued at $35,000 after acquiring an additional 365 shares in the last quarter. Hantz Financial Services Inc. raised its stake in shares of TG Therapeutics by 82.7% in the fourth quarter. Hantz Financial Services Inc. now owns 1,237 shares of the biopharmaceutical company's stock worth $37,000 after acquiring an additional 560 shares during the last quarter. Truvestments Capital LLC raised its stake in shares of TG Therapeutics by 172.4% in the fourth quarter. Truvestments Capital LLC now owns 1,621 shares of the biopharmaceutical company's stock worth $48,000 after acquiring an additional 1,026 shares during the last quarter. Finally, Kemnay Advisory Services Inc. acquired a new position in shares of TG Therapeutics during the fourth quarter worth approximately $52,000. 58.58% of the stock is owned by institutional investors.
Analyst Upgrades and Downgrades
Several analysts have recently commented on the stock. Zacks Research raised shares of TG Therapeutics from a "strong sell" rating to a "hold" rating in a research note on Monday, June 1st. JPMorgan Chase & Co. boosted their price objective on shares of TG Therapeutics from $65.00 to $72.00 and gave the stock an "overweight" rating in a research report on Friday, August 7th. Weiss Ratings reaffirmed a "hold (c+)" rating on shares of TG Therapeutics in a report on Wednesday, July 29th. B. Riley Financial increased their price objective on TG Therapeutics from $55.00 to $86.00 and gave the company a "buy" rating in a research report on Monday, July 27th. Finally, Jefferies Financial Group reiterated a "buy" rating and issued a $83.00 price objective on shares of TG Therapeutics in a research report on Monday, June 22nd. Five research analysts have rated the stock with a Buy rating, three have given a Hold rating and one has assigned a Sell rating to the company. Based on data from MarketBeat, TG Therapeutics currently has an average rating of "Hold" and an average price target of $63.00.
Read Our Latest Stock Analysis on TGTX
TG Therapeutics Stock Performance
Shares of NASDAQ:TGTX opened at $54.27 on Friday. The firm's 50 day simple moving average is $53.02 and its 200 day simple moving average is $40.90. TG Therapeutics, Inc. has a fifty-two week low of $26.76 and a fifty-two week high of $59.30. The company has a market capitalization of $8.31 billion, a price-to-earnings ratio of 19.81, a P/E/G ratio of 2.33 and a beta of 1.62. The company has a debt-to-equity ratio of 1.23, a current ratio of 4.27 and a quick ratio of 3.72.
TG Therapeutics (NASDAQ:TGTX - Get Free Report) last issued its quarterly earnings data on Monday, August 3rd. The biopharmaceutical company reported $0.05 earnings per share (EPS) for the quarter, missing analysts' consensus estimates of $0.31 by ($0.26). TG Therapeutics had a net margin of 55.22% and a return on equity of 73.49%. The firm had revenue of $240.34 million for the quarter, compared to analyst estimates of $229.77 million. During the same quarter in the prior year, the firm posted $0.17 EPS. The firm's revenue for the quarter was up 70.2% compared to the same quarter last year. As a group, sell-side analysts forecast that TG Therapeutics, Inc. will post 0.92 earnings per share for the current year.
TG Therapeutics Company Profile
(
Free Report)
TG Therapeutics, Inc is a clinical‐stage biopharmaceutical company headquartered in New York City that specializes in developing targeted therapies for hematological malignancies and autoimmune diseases. The company's research strategy focuses on the modulation of B-cell biology through novel antibody and small‐molecule agents. Since its founding in 2003, TG Therapeutics has built a diversified portfolio aimed at addressing unmet medical needs in oncology and immunology.
In December 2022, TG Therapeutics achieved its first commercial milestone when ublituximab-xiiy (marketed as Briumvi® in collaboration with Biogen) received U.S.
See Also
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.
Continue following MarketBeat
Add MarketBeat as your preferred source on Google to see our latest stories in your feed.
Before you consider TG Therapeutics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and TG Therapeutics wasn't on the list.
While TG Therapeutics currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Nuclear energy is entering a new growth cycle as rising power demand, expanding data centers, and renewed policy support bring the sector back into focus. After strong gains in recent years, the most impactful phase of nuclear investment may still be ahead.
This report highlights seven nuclear energy stocks positioned across the value chain—combining near-term revenue with long-term upside as next-generation technologies scale. Click the link below to unlock the full list.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
